Novonesis H1 2025 at a glance

Continued strong demand for biosolutions

90% organic sales growth 37.4% adjusted EBITDA margin

Novonesis narrows full-year outlook, lifting the lower end of financial guidance for organic sales growth

6-8%


(Prev. 5-8%)

37-38%

h adjusted EBITDA margin

Divisional sales performance organic





Divisional EBITDA margin

Adjusted EBITDA margin for Food & Health Biosolutions

38.4% Adjusted EBITDA margin for Planetary Health Biosolutions

Regional sales performance organic

Europe, the Middle East & Africa 10%	North America	Asia Pacific 8%	Latin America
37%	32%	19%	12%

% of sales